Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2015 | Pages:
344 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Pain - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Chronic Pain - Pipeline Review, H1 2015', provides an overview of the Chronic Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Chronic Pain Overview 12 Therapeutics Development 13 Pipeline Products for Chronic Pain - Overview 13 Pipeline Products for Chronic Pain - Comparative Analysis 14 Chronic Pain - Therapeutics under Development by Companies 15 Chronic Pain - Therapeutics under Investigation by Universities/Institutes 22 Chronic Pain - Pipeline Products Glance 23 Late Stage Products 23 Clinical Stage Products 24 Early Stage Products 25 Unknown Stage Products 26 Chronic Pain - Products under Development by Companies 27 Chronic Pain - Products under Investigation by Universities/Institutes 35 Chronic Pain - Companies Involved in Therapeutics Development 36 AbbVie Inc. 36 Acadia Pharmaceuticals Inc. 37 Adynxx, Inc. 38 Akron Molecules AG 39 Allergan, Inc. 40 arGEN-X BV 41 Astellas Pharma Inc. 42 Astraea Therapeutics, LLC 43 AstraZeneca PLC 44 BCN Peptides, S.A. 45 BioDelivery Sciences International, Inc. 46 Bionomics Limited 47 Cara Therapeutics, Inc. 48 ChironWells GmbH 49 Chromocell Corporation 50 Collegium Pharmaceutical, Inc. 51 CoLucid Pharmaceuticals, Inc. 52 Convergence Pharmaceuticals Ltd. 53 Creabilis SA 54 Cytogel Pharma, LLC 55 Daewoong Pharmaceutical Co., Ltd. 56 Daiichi Sankyo Company, Limited 57 Dompe Farmaceutici S.p.A. 58 DURECT Corporation 59 Egalet Corporation 60 Eli Lilly and Company 61 Endo Pharmaceuticals Inc. 62 Glenmark Pharmaceuticals Ltd. 63 Grunenthal GmbH 64 Johnson & Johnson 65 Kareus Therapeutics, SA 66 Kineta, Inc. 67 Kymab Limited 68 Laboratorios Del Dr. Esteve S.A. 69 Lohocla Research Corporation 70 Merck & Co., Inc. 71 Mertiva AB 72 Mesoblast Limited 73 Moberg Pharma AB 74 Mundipharma International Limited 75 Nanomerics Ltd 76 Nektar Therapeutics 77 Neura Therapeutik, LLC 78 Nippon Shinyaku Co., Ltd. 79 Orion Oyj 80 Pain Therapeutics, Inc. 81 Pfizer Inc. 82 Phosphagenics Limited 83 Purdue Pharma L.P. 84 Relmada Therapeutics, Inc. 85 Rottapharm SpA 86 Santen Pharmaceutical Co., Ltd. 87 Sea4Us 88 Shionogi & Co., Ltd. 89 Signature Therapeutics, Inc 90 Snowdon Inc. 91 Syntrix Biosystems, Inc. 92 Teikoku Pharma USA, Inc. 93 Teva Pharmaceutical Industries Limited 94 Trevena, Inc. 95 UMeWorld Limited 96 Zynerba Pharmaceuticals, Inc. 97 Chronic Pain - Therapeutics Assessment 98 Assessment by Monotherapy Products 98 Assessment by Combination Products 99 Assessment by Target 100 Assessment by Mechanism of Action 104 Assessment by Route of Administration 108 Assessment by Molecule Type 110 Drug Profiles 112 (celecoxib + tramadol hydrochloride) - Drug Profile 112 (oxycodone hydrochloride + naltrexone) ER - Drug Profile 113 A-836339 - Drug Profile 115 AAT-008 - Drug Profile 116 AGN-XX/YY - Drug Profile 117 AKR-201 - Drug Profile 118 APR-102 - Drug Profile 119 ARX-8203 - Drug Profile 120 ASP-7962 - Drug Profile 122 AXS-01 - Drug Profile 123 AXS-03 - Drug Profile 124 AYX-1 - Drug Profile 125 AYX-2 - Drug Profile 126 BBI-11008 - Drug Profile 127 bupivacaine hydrochloride - Drug Profile 128 buprenorphine hydrochloride - Drug Profile 130 buprenorphine hydrochloride depot - Drug Profile 132 buprenorphine hydrochloride ER - Drug Profile 133 cebranopadol - Drug Profile 134 celecoxib - Drug Profile 136 CNV-3000164 - Drug Profile 138 CNV-3000223 - Drug Profile 139 Conjugated Stigmine Program - Drug Profile 140 CR-701 - Drug Profile 141 CR-845 - Drug Profile 142 CRB-0022 - Drug Profile 144 CRB-0089 - Drug Profile 145 CT-340 - Drug Profile 146 Cyt-1010 - Drug Profile 147 DD-04107 - Drug Profile 149 dexmedetomidine hydrochloride - Drug Profile 150 DF-2593A - Drug Profile 152 Drugs for Chronic Pain and Inflammation - Drug Profile 153 Drugs for Chronic Pelvic Pain - Drug Profile 154 DS-1971 - Drug Profile 155 duloxetine hydrochloride DR - Drug Profile 156 DWJ-208 - Drug Profile 158 E-52862 - Drug Profile 159 Egalet-003 - Drug Profile 161 flurbiprofen - Drug Profile 162 FY-101C - Drug Profile 163 FY-103B - Drug Profile 164 GBR-900 - Drug Profile 165 Gene Therapy to Activate Endomorphin 2 for Chronic Pain - Drug Profile 166 Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 167 GIBH-1014 - Drug Profile 168 grapiprant - Drug Profile 169 HS-731 - Drug Profile 171 hydrocodone bitartrate - Drug Profile 172 hydrocodone bitartrate ER - Drug Profile 173 hydrocodone bitartrate ER - Drug Profile 175 hydrocodone bitartrate ER - Drug Profile 176 hydromorphone hydrochloride - Drug Profile 177 Kindolor - Drug Profile 178 KY-1017 - Drug Profile 180 LEVI-04 - Drug Profile 181 levorphanol tartrate ER - Drug Profile 182 lexanopadol - Drug Profile 183 mirogabalin - Drug Profile 184 Monoclonal Antibodies for Chronic Pain - Drug Profile 186 Monoclonal Antibodies to Block Nav1.7 for Chronic Pain - Drug Profile 187 morphine sulfate ER - Drug Profile 188 MPC-06ID - Drug Profile 189 NET-END - Drug Profile 191 NKTR-181 - Drug Profile 192 NL-001 - Drug Profile 194 NL-002 - Drug Profile 195 NM-0127 - Drug Profile 196 Omnitram - Drug Profile 197 onabotulinumtoxin A - Drug Profile 198 OSX-300 - Drug Profile 200 OSX-300 Backups - Drug Profile 201 oxycodone ER - Drug Profile 202 oxycodone hydrochloride ER - Drug Profile 204 oxycodone hydrochloride ER - Drug Profile 206 oxycodone hydrochloride ER - Drug Profile 207 oxycodone hydrochloride ER - Drug Profile 208 oxymorphone hydrochloride - Drug Profile 210 oxymorphone hydrochloride ER - Drug Profile 211 palmidrol - Drug Profile 212 Peptide to Block Calcium Channel for CNS Disorders - Drug Profile 213 Peptides to Inhibit Ion Channel for Chronic Pain - Drug Profile 214 PF-05089771 - Drug Profile 215 PF-06372865 - Drug Profile 217 PF-329 - Drug Profile 218 PF-6129 - Drug Profile 219 PF-614 - Drug Profile 220 PFR-03088 - Drug Profile 221 PFR-03318 - Drug Profile 222 PFR-03321 - Drug Profile 223 PFR-03323 - Drug Profile 224 PFR-03325 - Drug Profile 225 PFR-06158 - Drug Profile 226 PFR-06177 - Drug Profile 227 PRC-062 - Drug Profile 228 Prostatic Acid Phosphatase - Drug Profile 229 PTI-202 - Drug Profile 230 PTI-721 - Drug Profile 232 SA-14867 - Drug Profile 233 Small Molecule Agonizing ER-Beta for Neurology and Pain - Drug Profile 234 Small Molecule for Central Nervous System - Drug Profile 235 Small Molecule for Chronic Pain - Drug Profile 237 Small Molecule for Neuropathic Pain and Inflammatory Pain - Drug Profile 238 Small Molecule to Agonize mGlu2/3 for Chronic Pain - Drug Profile 239 Small Molecule to Antagonize TRPA1 for Chronic Pain - Drug Profile 240 Small Molecule to Block Cav2.2 Channel for Chronic Pain - Drug Profile 241 Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile 242 Small Molecule to Inhibit GPR-84 for Chronic Pain - Drug Profile 243 Small Molecule to Inhibit mPGES-1 for Chronic Pain - Drug Profile 244 Small Molecule to Inhibit P2Y14 for Chronic Pain - Drug Profile 245 Small Molecule to Modulate Ion Channel for Chronic Pain - Drug Profile 246 Small Molecules to Activate KCNQ Channels for Chronic Pain and CNS disorder - Drug Profile 247 Small Molecules to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 248 Small Molecules to Agonize NOP for Pain - Drug Profile 249 Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Drug Profile 250 Small Molecules to Antagonize P2X3 for Chronic Pain - Drug Profile 251 Small Molecules to Antagonize Tyrosine Kinase Receptor A for Chronic Pain - Drug Profile 252 Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 253 Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 254 Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain - Drug Profile 255 Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile 256 Small Molecules to Block Nav1.7 for Pain - Drug Profile 257 Small Molecules to Block TRPA1 and TRPV1 for CNS - Drug Profile 258 Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain - Drug Profile 259 SND-121 Prodrug - Drug Profile 260 sufentanil citrate - Drug Profile 261 Synthetic Peptide to Inhibit CRMP-2 Protein for Pain - Drug Profile 263 tapentadol hydrochloride - Drug Profile 264 tramadol hydrochloride SR - Drug Profile 265 TROX-1 - Drug Profile 266 TRV-734 - Drug Profile 267 U-2902 - Drug Profile 268 UMB-425 - Drug Profile 269 V-116517 - Drug Profile 270 VLNX-4975 - Drug Profile 271 YYC-301 - Drug Profile 272 ZEP-3 - Drug Profile 273 ZYN-001 - Drug Profile 275 Chronic Pain - Recent Pipeline Updates 276 Chronic Pain - Dormant Projects 315 Chronic Pain - Discontinued Products 322 Chronic Pain - Product Development Milestones 324 Featured News & Press Releases 324 Appendix 333 Methodology 333 Coverage 333 Secondary Research 333 Primary Research 333 Expert Panel Validation 333 Contact Us 333 Disclaimer 334
List of Tables Number of Products under Development for Chronic Pain, H1 2015 23 Number of Products under Development for Chronic Pain - Comparative Analysis, H1 2015 24 Number of Products under Development by Companies, H1 2015 26 Number of Products under Development by Companies, H1 2015 (Contd..1) 27 Number of Products under Development by Companies, H1 2015 (Contd..2) 28 Number of Products under Development by Companies, H1 2015 (Contd..3) 29 Number of Products under Development by Companies, H1 2015 (Contd..4) 30 Number of Products under Development by Companies, H1 2015 (Contd..5) 31 Number of Products under Investigation by Universities/Institutes, H1 2015 32 Comparative Analysis by Late Stage Development, H1 2015 33 Comparative Analysis by Clinical Stage Development, H1 2015 34 Comparative Analysis by Early Stage Development, H1 2015 35 Comparative Analysis by Unknown Stage Development, H1 2015 36 Products under Development by Companies, H1 2015 37 Products under Development by Companies, H1 2015 (Contd..1) 38 Products under Development by Companies, H1 2015 (Contd..2) 39 Products under Development by Companies, H1 2015 (Contd..3) 40 Products under Development by Companies, H1 2015 (Contd..4) 41 Products under Development by Companies, H1 2015 (Contd..5) 42 Products under Development by Companies, H1 2015 (Contd..6) 43 Products under Development by Companies, H1 2015 (Contd..7) 44 Products under Investigation by Universities/Institutes, H1 2015 45 Chronic Pain - Pipeline by AbbVie Inc., H1 2015 46 Chronic Pain - Pipeline by Acadia Pharmaceuticals Inc., H1 2015 47 Chronic Pain - Pipeline by Adynxx, Inc., H1 2015 48 Chronic Pain - Pipeline by Akron Molecules AG, H1 2015 49 Chronic Pain - Pipeline by Allergan, Inc., H1 2015 50 Chronic Pain - Pipeline by arGEN-X BV, H1 2015 51 Chronic Pain - Pipeline by Astellas Pharma Inc., H1 2015 52 Chronic Pain - Pipeline by Astraea Therapeutics, LLC, H1 2015 53 Chronic Pain - Pipeline by AstraZeneca PLC, H1 2015 54 Chronic Pain - Pipeline by BCN Peptides, S.A., H1 2015 55 Chronic Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2015 56 Chronic Pain - Pipeline by Bionomics Limited, H1 2015 57 Chronic Pain - Pipeline by Cara Therapeutics, Inc., H1 2015 58 Chronic Pain - Pipeline by ChironWells GmbH, H1 2015 59 Chronic Pain - Pipeline by Chromocell Corporation, H1 2015 60 Chronic Pain - Pipeline by Collegium Pharmaceutical, Inc., H1 2015 61 Chronic Pain - Pipeline by CoLucid Pharmaceuticals, Inc., H1 2015 62 Chronic Pain - Pipeline by Convergence Pharmaceuticals Ltd., H1 2015 63 Chronic Pain - Pipeline by Creabilis SA, H1 2015 64 Chronic Pain - Pipeline by Cytogel Pharma, LLC, H1 2015 65 Chronic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 66 Chronic Pain - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 67 Chronic Pain - Pipeline by Dompe Farmaceutici S.p.A., H1 2015 68 Chronic Pain - Pipeline by DURECT Corporation, H1 2015 69 Chronic Pain - Pipeline by Egalet Corporation, H1 2015 70 Chronic Pain - Pipeline by Eli Lilly and Company, H1 2015 71 Chronic Pain - Pipeline by Endo Pharmaceuticals Inc., H1 2015 72 Chronic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 73 Chronic Pain - Pipeline by Grunenthal GmbH, H1 2015 74 Chronic Pain - Pipeline by Johnson & Johnson, H1 2015 75 Chronic Pain - Pipeline by Kareus Therapeutics, SA, H1 2015 76 Chronic Pain - Pipeline by Kineta, Inc., H1 2015 77 Chronic Pain - Pipeline by Kymab Limited, H1 2015 78 Chronic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015 79 Chronic Pain - Pipeline by Lohocla Research Corporation, H1 2015 80 Chronic Pain - Pipeline by Merck & Co., Inc., H1 2015 81 Chronic Pain - Pipeline by Mertiva AB, H1 2015 82 Chronic Pain - Pipeline by Mesoblast Limited, H1 2015 83 Chronic Pain - Pipeline by Moberg Pharma AB, H1 2015 84 Chronic Pain - Pipeline by Mundipharma International Limited, H1 2015 85 Chronic Pain - Pipeline by Nanomerics Ltd, H1 2015 86 Chronic Pain - Pipeline by Nektar Therapeutics, H1 2015 87 Chronic Pain - Pipeline by Neura Therapeutik, LLC, H1 2015 88 Chronic Pain - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 89 Chronic Pain - Pipeline by Orion Oyj, H1 2015 90 Chronic Pain - Pipeline by Pain Therapeutics, Inc., H1 2015 91 Chronic Pain - Pipeline by Pfizer Inc., H1 2015 92 Chronic Pain - Pipeline by Phosphagenics Limited, H1 2015 93 Chronic Pain - Pipeline by Purdue Pharma L.P., H1 2015 94 Chronic Pain - Pipeline by Relmada Therapeutics, Inc., H1 2015 95 Chronic Pain - Pipeline by Rottapharm SpA, H1 2015 96 Chronic Pain - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 97 Chronic Pain - Pipeline by Sea4Us, H1 2015 98 Chronic Pain - Pipeline by Shionogi & Co., Ltd., H1 2015 99 Chronic Pain - Pipeline by Signature Therapeutics, Inc, H1 2015 100 Chronic Pain - Pipeline by Snowdon Inc., H1 2015 101 Chronic Pain - Pipeline by Syntrix Biosystems, Inc., H1 2015 102 Chronic Pain - Pipeline by Teikoku Pharma USA, Inc., H1 2015 103 Chronic Pain - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 104 Chronic Pain - Pipeline by Trevena, Inc., H1 2015 105 Chronic Pain - Pipeline by UMeWorld Limited, H1 2015 106 Chronic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 107 Assessment by Monotherapy Products, H1 2015 108 Assessment by Combination Products, H1 2015 109 Number of Products by Stage and Target, H1 2015 111 Number of Products by Stage and Mechanism of Action, H1 2015 115 Number of Products by Stage and Route of Administration, H1 2015 119 Number of Products by Stage and Molecule Type, H1 2015 121 Chronic Pain Therapeutics - Recent Pipeline Updates, H1 2015 286 Chronic Pain - Dormant Projects, H1 2015 325 Chronic Pain - Dormant Projects (Contd..1), H1 2015 326 Chronic Pain - Dormant Projects (Contd..2), H1 2015 327 Chronic Pain - Dormant Projects (Contd..3), H1 2015 328 Chronic Pain - Dormant Projects (Contd..4), H1 2015 329 Chronic Pain - Dormant Projects (Contd..5), H1 2015 330 Chronic Pain - Dormant Projects (Contd..6), H1 2015 331 Chronic Pain - Discontinued Products, H1 2015 332 Chronic Pain - Discontinued Products (Contd..1), H1 2015 333
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
